Myeloperoxidase is not a good biomarker for preeclampsia prediction

Abstract

Myeloperoxidase is a proinflammatory enzyme found to be increased in patients with established preeclampsia but never investigated before the disease onset. Here we examined myeloperoxidase concentration and activity in plasma and urine samples from pregnant women who remained normotensive throughout pregnancy and those who developed preeclampsia in order to assess its potential to predict this disorder. Our sample consisted of 30 cases who developed preeclampsia (14 severe and 16 mild) and 57 controls who remained healthy throughout pregnancy, derived from the Brazilian Ribeirão Preto and São Luís prenatal cohort (BRISA). Myeloperoxidase concentration were assessed using a commercial ELISA kit and enzymatic activity through tetramethylbenzidine oxidation. No statistical differences were found in myeloperoxidase levels nor activity between plasma or urine samples from controls, severe and mild cases. Myeloperoxidase did not seem to have a potential application for preeclampsia prediction.

Investigation of serum enzyme activities and oxidative stress markers in preeclampsia: a multiparameter analysis

“…MPO levels were not different in PE patients compared to controls [26]. Another recent study that had three groups as mild, severe PE patients and controls also have not found any difference in plasma MPO levels [27]. Our study showed that the MPO levels in patients have been found correlated with IDH, GDH and MDH.…”

Activation of a TLR9 mediated innate immune response in preeclampsia

“…In this study, we showed a significant increase in MPO in cases as early as 20 weeks’ gestation when compared with controls and this significant increase was equally evident at time of disease in preeclampsia. Previous studies measuring MPO in preeclampsia have reported conflicting results; some studies have reported no difference in MPO in preeclampsia in samples taken at 24 weeks or later in the third trimester 28,29 , whereas Gandley et al ., reported a 3-fold increase in circulating MPO levels in women with preeclampsia compared to matched healthy controls at 32–38 weeks’ gestation 30 . The variation in MPO levels in previous preeclampsia studies may be due to small sample size.…”

Circulating MicroRNAs in the Second Trimester From Pregnant Women Who Subsequently Developed Preeclampsia: Potential Candidates as Predictive Biomarkers and Pathway Analysis for Target Genes of miR-204-5p

“…Since most of the cases of PE occur after 25 weeks of gestation, we focused on the period of 20–25 weeks of gestation in order to maximize the chance to find predictive biomarkers to monitor the pregnancy. In this context, several candidates for circulating biomarkers have been studied, such as pregnancy-associated plasma protein-A (PAPP-A), C-reactive protein (CRP), interleukin-1β (IL-1β), antiangiogenic molecules, homocysteine, oxidative stress markers, and vasoactive peptides (Levine et al, 2004 ; D'antonio et al, 2013 ; Maged et al, 2017 ; Rocha-Penha et al, 2017 ; Lind Malte et al, 2018 ; Sandrim et al, 2018a , b ; Machado et al, 2019 ). However, most of these biomarkers showed poor to moderate predictive value for PE.…”